

1 **Clinical Sensitivity and Interpretation of PCR and Serological** 2 **COVID-19 Diagnostics for Patients Presenting to the Hospital**

3 Tyler E. Miller, M.D., Ph.D.^{1*}, Wilfredo F. Garcia Beltran, M.D., Ph.D.^{1*}, Adam Z. Bard, MBA,
4 MSF^{1*}, Tasos Gogakos, M.D., Ph.D.^{1*}, Melis N. Anahtar, M.D., Ph.D.¹, Michael Gerino
5 Astudillo, M.D.¹, Diane Yang, Ph.D.¹, Julia Thierauf, Ph.D.¹, Adam S. Fisch, M.D., Ph.D.¹,
6 Grace K. Mahowald, M.D., Ph.D.¹, Megan J. Fitzpatrick, M.D.¹, Valentina Nardi, M.D.¹, Jared
7 Feldman³, Blake M. Hauser³, Timothy M. Caradonna³, Hetal D. Marble, Ph.D.¹, Lauren L.
8 Ritterhouse, M.D., Ph.D.¹, Sara E. Turbett, M.D.^{1,2}, Julie Batten, MLS (ASCP)¹, Nicholas
9 Zeke Georgantas¹, Galit Alter, Ph.D.³, Aaron G. Schmidt, Ph.D.³, Jason B. Harris, M.D.⁴, Jeffrey
10 A. Gelfand, M.D.², Mark C. Poznansky, M.D., Ph.D.², Bradley E. Bernstein, M.D., Ph.D.¹,
11 David N. Louis, M.D.¹, Anand Dighe, M.D., Ph.D.¹, Richelle C. Charles, M.D.², Edward T.
12 Ryan, M.D.², John A. Branda, M.D.¹, Virginia M. Pierce, M.D.^{1,4}, Mandakolathur R. Murali,
13 M.D.^{1,5}, A. John Iafrate, M.D., Ph.D.¹, Eric S. Rosenberg, M.D.^{1,2}, Jochen Lennerz, M.D.,
14 Ph.D.^{1**}

- 15 1. Department of Pathology, Massachusetts General Hospital/Harvard Medical School,
16 Boston, MA, USA
17 2. Division of Infectious Diseases, Department of Medicine, Massachusetts General
18 Hospital/Harvard Medical School, Boston, MA, USA
19 3. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
20 4. Division of Infectious Diseases, Department of Pediatrics, Massachusetts General
21 Hospital/Harvard Medical School, Boston, MA, USA
22 5. Division of Allergy and Immunology, Department of Medicine, Massachusetts General
23 Hospital/Harvard Medical School, Boston, MA, USA

24
25 *These authors contributed equally

26
27 ** Correspondence should be addressed to Jochen Lennerz, M.D., Ph.D. at
28 jlennerz@partners.org

29
30
31

32 **Abstract (n=248 of 250)**

33

34 **Introduction:** The diagnosis of COVID-19 requires integration of clinical and
35 laboratory data. SARS-CoV-2 diagnostic assays play a central role in diagnosis and have
36 fixed technical performance metrics. Interpretation becomes challenging because the
37 clinical sensitivity changes as the virus clears and the immune response emerges. Our
38 goal was to examine the clinical sensitivity of two most common SARS-CoV-2
39 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the
40 disease course to provide insight into their clinical interpretation in patients presenting to
41 the hospital.

42 **Methods:** A single-center, retrospective study. To derive clinical sensitivity of PCR, we
43 identified 209 PCR-positive SARS-CoV-2 patients with multiple PCR test results (624
44 total PCR tests) and calculated daily sensitivity from date of symptom onset or first
45 positive test. To calculate daily clinical sensitivity by serology, we utilized 157 PCR-
46 positive patients with a total of 197 specimens tested by enzyme-linked immunosorbent
47 assay for IgM, IgG, and IgA anti-SARS-CoV-2 antibodies.

48 **Results:** Clinical sensitivity of PCR decreased with days post symptom onset with >90%
49 clinical sensitivity during the first 5 days after symptom onset, 70-71% from days 9-11,
50 and 30% at day 21. In contrast, serological sensitivity increased with days post symptom
51 onset with >50% of patients seropositive by at least one antibody isotype after day 7,
52 >80% after day 12, and 100% by day 21.

53 **Conclusion:** PCR and serology are complimentary modalities that require time-
54 dependent interpretation. Superimposition of sensitivities over time indicate that serology
55 can function as a reliable diagnostic aid indicating recent or prior infection.

56

57 **Introduction**

58 While many measures to mitigate the multifactorial impact of COVID-19 are being
59 implemented, one critical component of this strategy is the widespread testing and
60 identification of individuals currently or previously infected by SARS-CoV-2. The
61 delivery of effective care and mitigation of infection centers around the performance of
62 SARS-CoV-2 diagnostic testing and the clinical interpretation of results. The lack of a
63 full understanding of the natural history and immunopathogenesis of COVID-19 infection
64 creates unique challenges in the implementation of diagnostic testing strategies. SARS-
65 CoV-2 diagnostic assays have fixed technical performance metrics (e.g., sensitivity and
66 specificity). Clinical sensitivity depends on more than technical performance and is also
67 a function of pre-analytical variables and the disease state of the patient. Interpretation
68 becomes challenging because the clinical sensitivity changes as the virus clears and the
69 immune response emerges.

70

71 The goal of this study is to examine the clinical sensitivity and provide insights into the
72 interpretation of the two most common SARS-CoV-2 diagnostic test modalities: PCR and
73 serology. Laboratory-based diagnosis of active SARS-CoV-2 infection relies on the
74 direct detection of virus-specific nucleic acids, most commonly obtained from the
75 nasopharynx of infected patients. Indirect markers of infection include the detection of
76 SARS-CoV-2 specific antibodies, generated as part of the human immune response to the
77 virus. Serologic testing holds promise as a blood-based diagnostic aid, as a marker of
78 viral exposure, and potentially as an indicator of protective immunity. Understanding the
79 presence of these biomarker in relationship to one another and over the natural course of
80 infection is required to effectively utilize these available diagnostic tests in clinical
81 practice (1-3).

82

83 Here, we share our experience of SARS-CoV-2 PCR sensitivity and separately obtained
84 IgM, IgA, and IgG sensitivity of an in-house enzyme-linked immunosorbent assay
85 (ELISA) during the natural course of disease in a cohort of patients presenting to the
86 hospital.

87 **Methods**

88 **Setting and Design.** The study was designed as a single-center, retrospective review of
89 PCR results and serology data. PCR results were obtained between 3/3/2020 and
90 4/15/2020 and we superimposed serology data obtained from confirmed COVID-19
91 positive patients as part of ongoing clinical validation studies of an enzyme-linked
92 immunosorbent assay (ELISA) for regulatory approval. The study was conducted with
93 approval from the local Institutional Review Board.

94
95 **PCR.** Nucleic acid testing was performed as part of clinical care using three emergency-
96 use authorized real-time PCR assays. Our laboratory-developed real-time PCR assay uses
97 the Centers for Disease Control and Prevention primers targeting regions of the N gene of
98 SARS-CoV-2, the cobas SARS-CoV-2 Test performed on the cobas 6800 targets
99 regions of the ORF1a and E genes, and the Xpert Xpress SARS-CoV-2 assay run on the
100 GeneXpert Infinity targets regions of the N and E genes. The choice of testing platform
101 was determined by access to reagents available at the time of clinical testing provided for
102 patient care (see [supplement](#)).

103
104 **Serology.** An in-house enzyme-linked immunosorbent assay was used to measure IgG,
105 IgA, and IgM antibodies that target the SARS-CoV-2 receptor binding domain (RBD)
106 within the spike protein. The assay has been validated within MGH clinical laboratories
107 as a high-complexity molecular test (see [supplement](#)).

108
109 **Patient cohorts and statistical analysis.** An initial PCR-query was performed to
110 delineate clinical sensitivity over time, and analysis was restricted to patients
111 with multiple PCR test results and at least one positive. These patients were considered
112 confirmed COVID-19 positive and taken as true positives. In this subset, 83% were
113 inpatients, 13% were patients from the ED, and 4% were outpatients. We calculated
114 daily clinical sensitivity rates by dividing positive tests by all tests at each
115 day post symptom onset and after first positive PCR-test. To estimate the time when
116 PCR sensitivity reaches zero, we modeled a linear daily regression trend after first
117 positive PCR-test (see [supplement](#)).

118 Serologic analysis of IgM, IgA and IgG status was performed in a subset of all SARS-
119 CoV-2 PCR-positive patients and for each sample, we determined the days post symptom
120 onset at the collection date and calculated daily sensitivity for each antibody isotype as
121 well as sensitivity of any isotype. We plotted the sensitivity for both test modalities as
122 percentages per overlapping 5-day leading intervals against the days since symptom onset
123 (see [supplement](#)).

124

125 **Results**

126 **PCR sensitivity for SARS-CoV-2 nucleic acid decreased with days post symptom** 127 **onset**

128 SARS-CoV-2 viral RNA levels decline over the course of infection(4). This decline of
129 RNA levels clearly impacts the clinical sensitivity of PCR testing. It is not possible to
130 determine the false negative rate of the PCR test from patients with a single PCR result.
131 Therefore, we identified patients with multiple PCR tests who had at least one positive
132 test result (considered true positives). The resulting dataset is composed of 624 test
133 results from 209 patients (6.6% of all PCR-positive patients, [Table 1](#)). We compared this
134 subset to all tested patients ([Supplemental Figure 1, Supplemental Table 1](#)) and
135 contingency analysis of the multi-PCR vs. all single PCR-positive patient subset showed
136 no significant differences in age, gender, and test type ([Supplemental Table 1,](#)
137 [Supplemental Figure 2](#)). Thus, we consider the multi-PCR subset is demographically
138 representative of our tested patient population.

139 To derive clinical sensitivity over disease course, we needed to define an anchor point.
140 We chose two different anchor points: symptom onset (subjective) and first positive test
141 (objective). First, we examined the time-course by anchoring test results to the day of
142 symptom onset ([Figure 1, Supplemental Figure 3](#)). Clinical sensitivity remains above
143 90% for the first 5 days after symptom onset. In our cohort of patients presenting to the
144 hospital, patients were admitted to the hospital a median of 8 days after symptom onset
145 (interquartile range: 4-16 days; mean: 10 days), and between days 6-8, the clinical
146 sensitivity of PCR ranged from 84-76%. On subsequent days the sensitivity decreases,
147 and at day 18 the sensitivity decreases below 50%. We also compared sensitivity data
148 from an earlier study of mildly symptomatic patients(4) and noted a steeper PCR

149 sensitivity decline, consistent with viral levels dropping more quickly in this population
150 ([Supplemental Figure 4](#)). This data provides sensitivity estimates at the time of
151 presentation (e.g., a patient presents at day 10 after symptom onset). Second, we also
152 modeled how PCR sensitivity decreases over time after the first positive PCR-test
153 ([Supplemental Figure 3](#) and [Supplemental Figure 5](#)). Regression modeling and extension
154 of PCR-positivity decay (foot-point analysis) revealed that in our cohort, NP-swab
155 specimens could stay PCR-positive beyond 20 and up to 40 days ([Supplemental Figure](#)
156 [5](#)).

157

158 **Serological assay sensitivity increases with days post symptom onset**

159 Seroconversion is also a dynamic response to the virus and assay sensitivity changes over
160 time. To assess the sensitivity of our serology assay over time, we tested for IgM, IgG,
161 and IgA antibodies against the receptor binding domain (RBD) of SARS-CoV-2 spike
162 protein in a 157 SARS-CoV-2 PCR-positive patients using an in-house ELISA ([Table 1](#)).
163 For some patients, we were able to assess serology at multiple time points (n=591 total
164 isotype tests on 197 total specimens). Anchoring our serologic results to days after
165 symptom onset shows that seroconversion starts as early as symptom onset, is detectable
166 in 50% of subjects after day 7, and continues to increase with >80% of patients showing
167 seropositivity after day 12 ([Table 2](#), [Figure 1](#), [Supplemental Figure 4](#), [Supplemental](#)
168 [Table 2](#)). In the subset of patients with multiple serological tests we saw isotype
169 switching occur as short as 1-4 days, consistent with recent reports(5). Of note, we
170 detected IgA prior to IgM or IgG in a number of individuals, with 2 subjects having only
171 detectable IgA within 3 days of symptom onset. We also documented cases of IgG
172 positivity prior to IgM or IgA, highlighting the utility of measuring seroconversion using
173 all 3 isotypes ([Supplemental Table 3](#), [Supplemental Figure 6](#)). The superimposition of
174 serologic sensitivities with PCR sensitivities shows that, after day 7, seroconversion is a
175 reliable diagnostic aid indicating recent or prior infection ([Figure 1](#)).

176

177 **Discussion**

178 We present the dynamic clinical sensitivity of SARS-CoV-2 PCR and our serology
179 platform in patients presenting to the hospital. We performed this single-center,
180 retrospective analysis to share early real-world evidence that can inform interpretation of
181 PCR and serologic testing. We focused on assessing the clinical utility of both modalities
182 in conjunction by direct superimposition of both sensitivity time courses. The direct
183 superimposition shows that serology can function as a reliable diagnostic aid indicating
184 recent or prior infection – in particular at times when PCR sensitivity is lower than 70%.
185 Our findings emphasize that understanding the specific sensitivity kinetics of both
186 modalities is paramount for interpretation and effective utilization of SARS-CoV-2
187 diagnostics.

188

189 There is considerable interest in moving SARS-CoV-2 diagnostics to evidence-based
190 principles (6-9). While clinicians await formal guidance from large, prospective, multi-
191 center studies – which will be challenging during the ongoing pandemic – there is
192 considerable uncertainty surrounding SARS-CoV-2 diagnostics in clinical practice (3, 10-
193 13). Using available published data (3-7, 12, 14) and data presented here from our
194 hospital, we offer the following five diagnostic principles for consideration:

195

196 **(1) In symptomatic patients, all interpretations are anchored on days post symptom**
197 **onset.** Understanding performance characteristics of SARS-CoV-2 diagnostics over the
198 course of the infection is key to interpretation of results. We provide two distinct
199 approaches to anchor interpretation over the course of infection: subjective (date of
200 symptom onset) and objective (first PCR positive result). Both approaches are valid and
201 have limitations. For example, the quality of patient histories is variable and in many
202 cases the day of symptom onset is unknown or cannot easily be reconstructed. As a
203 practical suggestion and whenever available, we place the date of symptom onset in the
204 front page of the (electronic) medical record.

205 **(2) PCR is the diagnostic gold standard during acute infection.** PCR-testing using
206 consensus primers has an estimated specificity of >99% (15). Based on early reports
207 from Wuhan(16) the overall clinical sensitivity is reported around 70%. We found a

208 clinical sensitivity around 95% in the first five days after symptom onset and although
209 PCR is an imperfect standard concurrent IgM/IgA/IgG antibody assessment in the first 5
210 days post-symptom onset does not significantly aid in rendering a current diagnosis, and
211 at no point during active infection should serology replace PCR for diagnosis.

212 **(3) Clinical sensitivity of PCR decreases with days post symptom onset.** In clinical
213 practice many symptomatic patients present to medical care after day 1 of symptom
214 onset. Our data show PCR sensitivity decreases with days post-symptom onset ([Figure 1](#))
215 or days post first PCR-positive test result. Notably, some patients may have an initial
216 PCR-negative result at presentation ([Supplemental Figure 3](#)). Our data also indicate that
217 severely ill patients (many patients in our cohort) remain PCR-positive for a longer
218 period than mildly ill patients (patients in the Wölfel et al.(4) cohort). Both time and
219 disease severity may be key elements for the interpretation of PCR results.

220 **(4) Serological assay sensitivity increases with days post symptom onset.** In our
221 cohort and with our assay, clinical sensitivity of serologic testing surpasses that of PCR
222 after days 8-10 post symptom onset. Remarkably, we find seroconversion does not
223 follow the typical kinetics of IgM antibodies followed by class-switched IgG and IgA
224 antibodies. Rather, all appear simultaneously at a cohort level, with IgG or IgA
225 seropositivity preceding IgM responses in some cases. Supporting this are other studies
226 that report overall low IgM responses to SARS-CoV-2 that are often preceded by IgG(14,
227 17). These data highlight the benefit of measuring all three anti-SARS-CoV-2 antibody
228 isotypes to maximize sensitivity. In the case of SARS-CoV-2, it is unknown for how
229 long IgM, IgA or IgG antibodies remain detectable after infection. It is important to note
230 that a positive serologic result for IgM, IgA and/or IgG does not conclusively indicate
231 that a patient's presenting symptoms are due to a current SARS-CoV-2 infection.

232 **(5) Negative results do not completely preclude SARS-CoV-2 infection.**

233 Ruling out SARS-CoV-2 infection remains challenging. Supplementing PCR results
234 with serologic assessment can increase sensitivity (serology as a diagnostic aid).
235 However, our data clearly shows that there is a window period (day 6-12 from symptom
236 onset) when clinical sensitivity of PCR and serological assays are below 90%. In a
237 symptomatic patient, if multiple PCR tests are negative and serological results after 8-12
238 days are also negative, we believe the likelihood of active SARS-CoV-2 infection to be

239 low. Clinical judgement is needed in this situation as there are rare scenarios where PCR
240 negativity may be due to disease at a different anatomic site and/or serologic negativity
241 may be due to an immunocompromised state.

242

243 Limitations in our study include relatively small numbers, a retrospective design, and
244 selection bias due to the specific setting and testing practice. We evaluated symptomatic,
245 mostly hospitalized patients and we cannot derive recommendations for asymptomatic or
246 mildly symptomatic patients from our data. Due to limited availability of tests and time
247 constraints during an ongoing pandemic, we do not have daily samples. Date of
248 symptom onset is not consistently available, subjective, and affected by recall biases –
249 yet, it represents a useful anchor point for disease time course in symptomatic patients.
250 Notably, the eclipse period ranges from 2-14 days (18-21) and some patients already
251 mounted a serologic response at the time of presentation, which can be taken as an
252 argument for the early y-axis deviation from zero in the serology curve and a
253 confirmation of date of symptom onset as an imperfect marker. We caution that the
254 presented serology data are specific to our ELISA, and we cannot extrapolate to anti-
255 SARS-CoV-2 antibody responses in general. Nonetheless, other publications indicate
256 that the time courses are comparable (14, 17, 22). Our serological studies measured
257 antibodies to the RBD of SARS-CoV-2. We chose this viral antigen because of its
258 specificity to SARS-CoV-2, and because anti-RBD antibodies are typically neutralizing.
259 Plaque reduction neutralization tests are the gold-standard for assessing neutralizing
260 ability (23-26), and ongoing studies are in progress to confirm anti-RBD antibodies are
261 neutralizing in SARS-CoV-2 infection (27). Some commercially available assays
262 measure the more abundant nucleocapsid protein, which may increase sensitivity to
263 detect a serologic response early in the course of infection, therefore shifting the
264 seroconversion curve to the left. However, antibodies to nucleocapsid protein are
265 unlikely to provide protective immunity as nucleocapsid protein is inaccessible to
266 antibodies in an intact virus. Therefore, serology results also likely depend on the
267 specific antigen being employed in testing. Finally, our multi-PCR cohort and serologic
268 patient cohort are largely non-overlapping (n=20/209) PCR-positive patient. To enable
269 additive sensitivity calculations from combined PCR and serology assays, prospective

270 and systematically obtained repeated parallel PCR and quantitative serologic data will be
271 necessary.

272

273 Determining the clinical sensitivity of SARS-CoV-2 diagnostic tests is an area that does
274 not have time to wait for full, exact analysis during an ongoing pandemic. Our real-
275 world data outline the strengths and weaknesses of two SARS-CoV-2 test modalities over
276 the natural course of infection. We hope these data, in conjunction with the 5 diagnostic
277 principles for consideration, can contribute to effective utilization and interpretation of
278 COVID-19 related laboratory data for patient care.

279 **Acknowledgments**

280 The authors thank all patients and laboratory staff for making this study possible.
281 CR3022 reference sequences, CR3022-IgA and CR3022-IgM isotypes, and ELISA
282 protocols were kindly provided by Stephanie Fischinger, Caroline Atyeo, and Matthew
283 Slein from the laboratory of Dr. Galit Alter (Ragon Institute). We thanks Yael Heher MD
284 for excellent discussions. ELISA protocols were developed and optimized with the
285 laboratory of Dr. Alejandro Balazs (Ragon Institute). This work is also in part supported
286 by NIH (RO1 CA225655) to J.K.L, Centers for Disease Control and Prevention
287 U01CK000490 (E.T.R., R.C.C.), NIGMS training grant T32 GM007753 (B.M.H.,
288 T.M.C), NIH R01 AI146779 (A.G.S.) The content is solely the responsibility of the
289 authors and does not necessarily represent the official views of the National Institute of
290 Health or any other organization.
291

292 **References**

293

- 294 1. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic
295 Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative
296 Review. *Ann Intern Med.* 2020;172(11):726-34.
- 297 2. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early Humoral Response
298 to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis.* 2020.
- 299 3. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.
300 *JAMA.* 2020.
- 301 4. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al.
302 Virological assessment of hospitalized patients with COVID-2019. *Nature.* 2020.
- 303 5. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
304 shedding and transmissibility of COVID-19. *Nat Med.* 2020.
- 305 6. Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based
306 management guideline for the COVID-19 pandemic - Review article. *Int J Surg.*
307 2020;77:206-16.
- 308 7. Pascarella G, Strumia A, Piliengo C, Bruno F, Del Buono R, Costa F, et al. COVID-19
309 diagnosis and management: a comprehensive review. *J Intern Med.* 2020.
- 310 8. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19:
311 Current Issues and Challenges. *J Clin Microbiol.* 2020;58(6).
- 312 9. Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. *Sci Transl Med.*
313 2020;12(546).
- 314 10. Bermingham WH, Wilding T, Beck S, Huissoon A. SARS-CoV-2 serology: Test, test,
315 test, but interpret with caution! *Clin Med (Lond).* 2020.
- 316 11. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians.
317 *Clin Microbiol Infect.* 2020.
- 318 12. Pulia MS, O'Brien TP, Hou PC, Schuman A, Sambursky R. Multi-tiered screening and
319 diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to
320 pandemic. *Ann Med.* 2020:1-8.
- 321 13. Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19
322 Antibody Tests - At What Cost? *N Engl J Med.* 2020.
- 323 14. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to
324 SARS-CoV-2 in patients with COVID-19. *Nat Med.* 2020.
- 325 15. Lu X 2020;Pageshttps://wwwnc.cdc.gov/eid/article/26/8/20-1246_article2020.

- 326 16. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in
327 Different Types of Clinical Specimens. *JAMA*. 2020.
- 328 17. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies
329 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*.
330 2020.
- 331 18. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus
332 (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. *Euro*
333 *Surveill*. 2020;25(5).
- 334 19. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation
335 Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed
336 Cases: Estimation and Application. *Ann Intern Med*. 2020;172(9):577-82.
- 337 20. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
338 Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*.
339 2020;382(13):1199-207.
- 340 21. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al.
341 Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus
342 Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data.
343 *J Clin Med*. 2020;9(2).
- 344 22. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-
345 CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis*. 2020.
- 346 23. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al.
347 Potent neutralizing antibodies from COVID-19 patients define multiple targets of
348 vulnerability. *Science*. 2020.
- 349 24. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, et al. Identification of a critical neutralization
350 determinant of severe acute respiratory syndrome (SARS)-associated coronavirus:
351 importance for designing SARS vaccines. *Virology*. 2005;334(1):74-82.
- 352 25. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent
353 SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal
354 model. *Science*. 2020.
- 355 26. Sun Z, Chen C, Li W, Martinez DR, Drelich A, Baek DS, et al. Potent neutralization of
356 SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large
357 library with a new stable scaffold. *MAbs*. 2020;12(1):1778435.
- 358 27. Ju B, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.
359 bioRxiv 2020.03.21.990770. 2020.

360 **Tables**

361

362 **Table 1. Demographics of cohorts used in analysis.**

| | PCR Total n (%) | PCR-positive n (%) | PCR Multiple Tests n (%) | Serology n (%) |
|-----------------|--------------------|-----------------------|-----------------------------|----------------------|
| Patients | 11,698 | 3,163 (27) | 209 | 157 |
| Age | | | | |
| Median | 46 | 47 | 46 ^a | 57 ^a |
| Average | 47.0 | 48.0 | 48.6 | 57 |
| Range | 0 to 102 | 0 to 102 | 21 to 93 | 22 to 98 |
| Gender | | | | |
| Female | 6,411 (55) | 1,584 (25) | 110 (53) ^b | 55 (35) ^b |
| Male | 5,270 (45) | 1,576 (30) | 99 (47) | 102 (65) |
| Other | 22 (0.2) | 3 (14) | 0 | 0 |

363

364 PCR-positive is the SARS-CoV-2 PCR-positive subset of the all tested patients (PCR
365 Total). PCR Multiple Tests is a cohort of patients with multiple PCR test results (and at
366 least one positive result) used for clinical sensitivity analysis shown in Figure 1.

367 Serology is an independent subset of PCR-positive patients. ^a, P<0.01 from student t-test;

368 ^b, P<0.01 from Fisher's exact test.

369

370 **Table 2. Sensitivity of anti-SARS-CoV-2 serology by isotype, age, gender, and days**
371 **post symptom onset.**


372

| Total specimens tested | 197 | | Male | Female | Age < 70 | Age ≥ 70 |
|--------------------------------|------------|----------|-----------------|-------------------|--------------------|-----------------|
| Days post symptom onset | n | % | (% male) | (% female) | (% < 70) | (% ≥ 70) |
| < 8 days (total) | 60 | | 39 | 21 | 34 | 26 |
| Positive for IgG | 9 | 15% | 7 (18) | 2 (10) | 6 (18) | 3 (12) |
| Positive for IgG or IgM | 12 | 20% | 9 (23) | 3 (14) | 9 (26) | 3 (12) |
| Positive for IgG or IgM or IgA | 15 | 25% | 12 (31) | 3 (14) | 10 (28) | 5 (12) |
| 8 to 14 days (total) | 85 | | 58 | 27 | 70 | 15 |
| Positive for IgG | 45 | 53% | 33 (57) | 12 (44) | 40 (57) | 5 (33) |
| Positive for IgG or IgM | 53 | 62% | 38 (66) | 15 (56) | 45 (64) | 8 (53) |
| Positive for IgG or IgM or IgA | 58 | 68% | 40 (69) | 18 (67) | 50 (71) | 8 (53) |
| >14 days (total) | 52 | | 35 | 17 | 47 | 5 |
| Positive for IgG | 46 | 88% | 30 (86) | 16 (94) | 42 (89) | 4 (80) |
| Positive for IgG or IgM | 47 | 90% | 31 (89) | 16 (94) | 43 (91) | 4 (80) |
| Positive for IgG or IgM or IgA | 49 | 94% | 33 (94) | 16 (94) | 45 (96) | 4 (80) |

373

374 **Figures**

375



376

377

378 **Figure 1: Sensitivity by assay modality over time.** Blood-based serologic sensitivity in
 379 157 patients superimposed onto NP swab PCR data from 209 patients. Results for all
 380 patient samples from initial symptom onset are plotted: PCR – 516, Serology – 588 (196
 381 samples x 3 isotypes). Serology sensitivity is based on detection of IgM, IgG, or IgA.
 382 Sample results prior to day 0 were excluded. PCR and serology samples were obtained in
 383 largely different patient populations; therefore, sensitivities are not additive. Data is
 384 plotted as 5-day moving average against the days since symptom onset. NA: none
 385 assessed.

386

387

388